Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713490 · ClinicalTrials.gov registry record · Phase 4
Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty
A Phase 4 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT02713490 is a Phase 4 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 140 participants.
The verdict
NCT02713490, a Phase 4 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
This is a Phase 4, multicenter, randomized, double-blind, controlled trial in approximately 140 adult subjects undergoing primary unilateral TKA under spinal anesthesia with bupivacaine HCl (10-15 mg).
Interventions
- DRUG Bupivacaine
- DRUG EXPAREL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-04-18 |
| Est. Completion | 2017-02-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02713490
The ClinicalTrials.gov registry entry for NCT02713490 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT02713490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02713490 about?
NCT02713490 is a clinical study titled "Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty". This is a Phase 4, multicenter, randomized, double-blind, controlled trial in approximately 140 adult subjects undergoing primary unilateral TKA under spinal anesthesia with bupivacaine HCl (10-15 mg).
What is the current status of trial NCT02713490?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2016-04-18. Estimated completion is 2017-02-08.
What interventions are being tested in trial NCT02713490?
The interventions under investigation include: Bupivacaine (DRUG), EXPAREL (DRUG).
Who is sponsoring clinical trial NCT02713490?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.